CRISPR’s other patent interference 

CRISPR-based gene editing has been an IP battleground for the past decade, and the conflicts don’t end at therapeutic applications in human cells. A quieter fight over inventorship has been brewing among the small group of companies editing bacterial cells for human therapeutics.

The fight for editing rights in bacterial cells involves a limited set of applications, a subset of the technology and a few biotech players, at least for now. However, the outcome could have broader implications for patent eligibility and how claims can be challenged...